Replies to post #6274 on Biotech Values

[DewDiligence]

That was an amusing AIDS blurb. Now fast-forward 13 years to the 2003 acquisition of ISI by HEB:

“…We believe that Hemispherx has a unique broad based experimental platform of immune based therapies that shows substantial potential to benefit the scientific community regarding HIV/AIDS, CFS, hepatitis, bioterror, multiple sclerosis, cancer and various sexually transmitted viral infections."

http://www.biospace.com/news_story.cfm?StoryID=11978220&full=1

No discussion required.